Supplementary Table 2: Incidence of study drug related maximum Grade 3/4 toxicities (N = 70)

CTCAE toxicity	Patients with toxicity, n (%)	
	Grade 3	Grade 4
Non-laboratory toxicities		
Fatigue	12 (17.1)	1 (1.4)
Nausea	7 (10.0)	0
Diarrhea	5 (7.1)	2 (2.9)
Vomiting	6 (8.6)	0
Anorexia	3 (.3)	0
Thrombosis	2 (2.9)	1 (1.4)
Dehydration	2 (2.9)	0
Skin infections	2 (2.9)	0
Renal failure	2 (2.9)	0
Laboratory toxicities		
Neutropenia	6 (8.6)	4 (5.7)
Anemia	8 (11.4)	1 (1.4)
Thrombocytopenia	1 (1.4)	4 (5.7)
Hypokalemia	3 (4.3)	04
Leukopenia	2 (2.9)	1 (1.4)
Lymphopenia	2 (2.9)	1 (1.4)

Abbreviations: CTCAE, Common Toxicity Criteria for Adverse Events; N, total number of patients in population; n, number of patients with ≥ 1 toxicity of the respective maximum grade.

Note: 1 patient experienced Grade 5 study drug related laboratory toxicity (neutropenia during Cycle 3 of pemetrexed/cisplatin induction treatment).